| Autor: |
He S; Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.; FuRong Laboratory, Changsha 410078, China., Lin F; Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.; FuRong Laboratory, Changsha 410078, China., Hu X; Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.; FuRong Laboratory, Changsha 410078, China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China.; Hunan Engineering Research Center for Intelligent Diagnosis and Treatment of Respiratory Disease, Changsha 410008, China., Pan P; Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.; FuRong Laboratory, Changsha 410078, China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China.; Hunan Engineering Research Center for Intelligent Diagnosis and Treatment of Respiratory Disease, Changsha 410008, China. |
| Abstrakt: |
The gut microbiota plays a crucial role in the human microenvironment. Dysbiosis of the gut microbiota is a common pathophysiological phenomenon in critically ill patients. Therefore, utilizing intestinal microbiota to prevent complications and improve the prognosis of critically ill patients is a possible therapeutic direction. The gut microbiome-based therapeutics approach focuses on improving intestinal microbiota homeostasis by modulating its diversity, or treating critical illness by altering the metabolites of intestinal microbiota. There is growing evidence that fecal microbiota transplantation (FMT), selective digestive decontamination (SDD), and microbiota-derived therapies are all effective treatments for critical illness. However, different treatments are appropriate for different conditions, and more evidence is needed to support the selection of optimal gut microbiota-related treatments for different diseases. This narrative review summarizes the curative effects and limitations of microbiome-based therapeutics in different critically ill adult patients, aiming to provide possible directions for gut microbiome-based therapeutics for critically ill patients such as ventilator-associated pneumonia, sepsis, acute respiratory distress syndrome, and COVID-19, etc. |
